47 completed, 20 recruiting, 15 terminated, 9 active not recruiting. 107 Phase 2, 31 Phase 1, 1 Phase 3.
Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis bomedemstat - Myelofibrosis | Phase 2 | Not yet recruiting | United Lincolnshire Hospitals NHS Trust | 40 | 2026-11-01 | 2026-02-20 |
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera | Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-11-01 | 2026-10-16 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis TQ05105 Tablets (Rovadicitinib Tablets) - Myelofibrosis | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 51 | 2026-06-18 | 2026-07-15 |
| Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow Nelfinavir - Myelofibrosis, Myelofibrosis; Anemia | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 10 | 2025-09-16 | 2026-10-26 |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C - AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL) | Phase 2 | Recruiting | Center for International Blood and Marrow Transplant Research | 358 | 2025-07-25 | 2026-03-17 |
| Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition Tasquinimod - Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 20 | 2025-02-20 | 2025-03-07 |
| A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis Ulixertinib, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 37 | 2025-01-07 | 2026-07-28 |
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam - Splenomegaly, Myelofibrosis | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-10-01 | 2026-09-16 |
| RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis RVU120, Ruxolitinib - Myelofibrosis | Phase 2 | Terminated | Ryvu Therapeutics SA | 36 | 2024-09-19 | 2026-09-16 |
| A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis Ruxolitinib, INCB57643 - Myelofibrosis | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-09-11 | 2025-05-22 | |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 216 | 2024-07-09 | 2026-10-23 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) TQ05105 tablets, TQB3909 tablets - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 21 | 2024-05-13 | 2026-01-05 |
| A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib - Myelofibrosis, Moderate Thrombocytopenia | Phase 2 | Recruiting | Karyopharm Therapeutics Inc | 58 | 2024-04-22 | 2026-02-12 |
| Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia | Phase 2 | Recruiting | University of Southern California | 30 | 2024-03-01 | 2026-03-27 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) TQ05105 Tablets, TQB3617 Capsules - Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 92 | 2023-12-12 | 2025-12-08 |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT) - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 313 | 2023-12-08 | 2026-08-17 |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
Showing 20 of 107. Sign in to see all of them.
Primary Myelofibrosis (107) · Myelodysplastic Syndromes (27) · Leukemia, Myeloid, Acute (24) · Myeloproliferative Disorders (22) · Leukemia, Lymphocytic, Chronic, B-Cell (21) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (20) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (20) · Lymphoma, Non-Hodgkin (16) · Polycythemia Vera (16) · Leukemia, Myelomonocytic, Chronic (14) · Hodgkin Disease (13) · Leukemia (11) · Multiple Myeloma (11) · Thrombocythemia, Essential (10) · Lymphoma (8)
Hemic and Lymphatic Diseases (107) · Bone Marrow Diseases (104) · Hematologic Diseases (104) · Myeloproliferative Disorders (85) · Neoplasms (48) · Neoplasms by Histologic Type (38) · Pathological Conditions, Signs and Symptoms (36) · Pathologic Processes (34) · Disease Attributes (33) · Chronic Disease (32) · Leukemia, Myeloid (30) · Immune System Diseases (29) · Leukemia (28) · Immunoproliferative Disorders (26) · Lymphatic Diseases (26)
ruxolitinib (26) · Cyclophosphamide (13) · fludarabine phosphate (10) · Whole-Body Irradiation (9) · fludarabine (9) · Mycophenolic Acid (8) · Busulfan (7) · Tacrolimus (7) · Peripheral Blood Stem Cell Transplantation (6) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (5) · Stem Cell Transplantation (5) · Cyclosporine (4) · Melphalan (4) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (4) · fedratinib (4)
M.D. Anderson Cancer Center (12) · City of Hope Medical Center (5) · John Mascarenhas (5) · Incyte Corporation (4) · Bristol-Myers Squibb (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Masonic Cancer Center, University of Minnesota (3) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (3) · Center for International Blood and Marrow Transplant Research (2) · Fred Hutchinson Cancer Center (2) · French Innovative Leukemia Organisation (2) · Gruppo Italiano Trapianto di Midollo Osseo (2) · Kartos Therapeutics, Inc. (2) · Karyopharm Therapeutics Inc (2) · Memorial Sloan Kettering Cancer Center (2)
United States (81) · Italy (22) · Germany (17) · Spain (15) · France (14) · Australia (12) · Poland (10) · Belgium (9) · Canada (9) · United Kingdom (9) · China (7) · Israel (7) · South Korea (6) · Netherlands (5) · Austria (4)
John Mascarenhas, MD (5) · Ryotaro Nakamura, MD (3) · Ayalew Tefferi, MD (2) · Prithviraj Bose (2) · Raajit Rampal, MD, PhD (2) · Ronald Hoffman, MD (2) · Srdan Verstovsek, M.D. (2) · Srdan Verstovsek, MD, PhD (2) · Uday Popat, MD (2) · Abdulraheem Yacoub, MD (1) · Alessandro Rambaldi, MD (1) · Amy E DeZern, MD (1) · Amy Zhou, M.D. (1) · Andrew M Yeager, MD (1)
PMID 41758981, PMID 10204198, PMID 18997171, PMID 19706886, PMID 19720904, PMID 19812383, PMID 20008298, PMID 20709666, PMID 20843246, PMID 22718840, PMID 22766223, PMID 23812932, PMID 24327518, PMID 24355079, PMID 24963042, PMID 25563429, PMID 25762180, PMID 27424289, PMID 27760761, PMID 27931243, PMID 28672195, PMID 29073967, PMID 29383130, PMID 29544547, PMID 29846250, PMID 31101621, PMID 31533931, PMID 31778911, PMID 31831767, PMID 31882719, PMID 31894292, PMID 32040960, PMID 33609248, PMID 34138638, PMID 34288026, PMID 36881782, PMID 37530627, PMID 38259250, PMID 40241543, PMID 40334082, PMID 40919483, PMID 41146971, PMID 41875235, PMID 42054549, PMID 42253638
P01CA108671 (6), 2015 (2), 2018 (2), 2023 (2), 2019 (1), P01CA015396 (1), P30CA014089 (1), P30CA033572 (1), R01CA077544 (1), R01CA181045 (1), R01CA266783 (1), U54HL081030 (1), UM1CA186691 (1)